# Key CBD Epilepsy Studies: The Strongest Evidence

By Robin Roy Krigslund-Hansen | 12+ years in CBD industry
Last updated: January 21, 2026

---

## Quick Summary

CBD epilepsy research represents the strongest clinical evidence in cannabinoid medicine, with multiple large-scale randomised controlled trials leading to FDA and EMA approval of Epidiolex for treatment-resistant epilepsies. These studies provide the gold standard for CBD clinical research.

---

## Key Takeaways

- FDA-approved for specific epilepsies
- Multiple Phase III trials completed
- Significant seizure reduction demonstrated
- Well-documented safety profile
- Sets standard for CBD research

---

## Approved Indications

### Epidiolex (CBD) Approval

**FDA Approved For:**
- Dravet syndrome
- Lennox-Gastaut syndrome
- Tuberous sclerosis complex

**EMA Approved For:**
- Dravet syndrome
- Lennox-Gastaut syndrome
- (With clobazam)

---

## Dravet Syndrome Trials

### Devinsky et al. (2017) - Landmark Study

**Study Details:**
- Design: Double-blind, placebo-controlled RCT
- Participants: 120 children and young adults
- Dose: 20 mg/kg/day CBD
- Duration: 14 weeks
- Population: Drug-resistant Dravet syndrome

**Key Results:**
- CBD group: 38.9% seizure reduction
- Placebo group: 13.3% reduction
- 5% of CBD group seizure-free
- Significant difference (p=0.01)

**Secondary Outcomes:**
- Improved overall condition ratings
- Caregiver global impression improved
- Quality of life benefits

**Significance:**
- First major RCT for CBD in epilepsy
- Led to FDA approval
- Established CBD as legitimate medicine

### GWPCARE1 Extension Study

**Long-Term Findings:**
- Sustained efficacy
- Up to 4 years follow-up
- Maintained seizure reduction
- Safety profile established

---

## Lennox-Gastaut Syndrome Trials

### Devinsky et al. (2018) - LGS Study

**Study Details:**
- Design: Double-blind, placebo-controlled
- Participants: 225 patients
- Doses: 10 and 20 mg/kg/day
- Duration: 14 weeks

**Key Results:**
- Drop seizures reduced significantly
- 10 mg: 37% reduction
- 20 mg: 42% reduction
- Placebo: 17% reduction

**Additional Findings:**
- Both doses effective
- Higher dose slightly more effective
- Also more side effects at higher dose
- Dose optimisation guidance

### Thiele et al. (2018) - Second LGS Trial

**Study Details:**
- Design: Double-blind, placebo-controlled
- Participants: 171 patients
- Dose: 20 mg/kg/day
- Duration: 14 weeks

**Key Results:**
- 44% reduction in drop seizures (CBD)
- 22% reduction (placebo)
- Consistent with first trial
- Replication of findings

---

## Tuberous Sclerosis Complex

### Thiele et al. (2021) - GWPCARE6

**Study Details:**
- Design: Double-blind, placebo-controlled
- Participants: 224 patients
- Doses: 25 and 50 mg/kg/day
- Duration: 16 weeks

**Key Results:**
- 48.6% seizure reduction (25 mg)
- 47.5% reduction (50 mg)
- 26.5% reduction (placebo)
- Led to TSC approval

---

## Safety Profile

### Common Side Effects

**From Trials:**
- Somnolence (drowsiness)
- Decreased appetite
- Diarrhea
- Liver enzyme elevations
- Fatigue

### Serious Considerations

**Liver Function:**
- Elevated ALT/AST in some patients
- Monitoring recommended
- Usually reversible
- More common with valproate

### Drug Interactions

**Notable:**
- Clobazam levels increased
- Valproate interaction
- CYP450 effects
- Monitoring required

---

## Dose-Response Findings

### What Trials Showed

**Optimal Dosing:**
- 10-20 mg/kg/day effective
- Higher doses: more effect but more side effects
- 20 mg/kg/day most common
- Titration recommended

### Consumer Product Comparison

**Important Context:**
- Trial doses: Often 1000mg+/day
- Consumer products: Often 25-100mg/day
- Direct comparison problematic
- Different use contexts

---

## Mechanism Insights

### From Clinical Observations

**Proposed Mechanisms:**
- GPR55 antagonism
- TRPV1 modulation
- Adenosine reuptake
- Possible sodium channel effects
- Not fully understood

---

## Historical Context

### Charlotte's Web Story

**Background:**
- Charlotte Figi (Dravet syndrome)
- Dramatic improvement with CBD oil
- Media attention
- Spurred research and legislation

**Impact:**
- Increased public awareness
- Research funding support
- Legal changes
- Pharmaceutical development

---

## Comparison to Other Epilepsy Drugs

### How CBD Compares

**Efficacy:**
- Comparable to add-on therapies
- For drug-resistant cases
- Not first-line treatment
- Adjunctive use

**Safety:**
- Favourable profile generally
- Liver monitoring needed
- Drug interactions
- Generally well-tolerated

---

## What This Means for CBD

### Broader Implications

**For CBD Research:**
- Proves CBD can meet approval standards
- Demonstrates rigorous evaluation possible
- Sets methodology precedent
- Validates pharmaceutical potential

**For Consumers:**
- Strongest efficacy evidence
- Safety data available
- Informs expectations
- Different from supplement doses

---

## Limitations

### Still Unknown

- Long-term effects (decades)
- Optimal formulations
- Mechanism details
- Predictors of response

### Study Population vs General Use

- Trials in severe, rare epilepsies
- Not generalisable to all seizure types
- Specific patient populations
- Supervised medical use

---

## My Take

The epilepsy trials represent CBD's coming-of-age as a medicine. Multiple large, well-designed RCTs leading to FDA approval is the gold standard we should apply when evaluating other CBD claims. This evidence sets a benchmark: when CBD is properly studied, it can either prove or disprove efficacy. The success here shows CBD is a legitimate medicine for specific conditionsâ€”while also highlighting how much more research other uses need.

---

## Related Articles

- [CBD for Epilepsy](/conditions/epilepsy)
- [Charlotte's Web Story](/knowledge/charlottes-web-story)
- [Understanding CBD Studies](/knowledge/understanding-cbd-studies)

---

*This article is for educational purposes only. Epilepsy requires medical supervision.*
